SETDB1 Antibody

What is SETDB1 and why is it significant for immunological research?

SETDB1 is an H3K9 methyltransferase that belongs to the histone-lysine methyltransferase family. It is a SET domain protein that specifically methylates lysine 9 of histone H3, creating a tag for epigenetic transcriptional repression by recruiting HP1 proteins (CBX1, CBX3, and/or CBX5) . SETDB1 plays crucial roles in immune cell function and development, including B cell maturation, T cell activity regulation, and immune escape mechanisms in cancer cells . Originally discovered over two decades ago, SETDB1's function in the immune response wasn't reported until 2011, making it a relatively new target in immunological research .

What types of SETDB1 antibodies are available for research applications?

Two main types of SETDB1 antibodies are available for research:

Both types are available in different formats (purified, BSA-free) and have been validated for various applications including Western blotting, immunohistochemistry, and immunofluorescence .

What is the expected molecular weight of SETDB1 in Western blot analysis?

While the calculated molecular weight of SETDB1 is approximately 143 kDa, the observed molecular weight in Western blot analysis typically ranges from 170-180 kDa . Different antibodies may detect slightly different bands:

• Mouse monoclonal antibody (clone 5H6D4) detects a band of approximately 180 kDa in HEK293 cell lysates

• Polyclonal rabbit antibodies detect bands of 170-180 kDa in various cell types including HeLa, HEK-293, MCF-7, Jurkat, and HepG2 cells

The difference between calculated and observed molecular weight may be due to post-translational modifications, post-translation cleavages, relative charges, and other experimental factors .

What species reactivity can be expected with SETDB1 antibodies?

SETDB1 antibodies show reactivity with multiple species:

Cross-reactivity may vary between antibodies and applications, so validation in your specific experimental system is recommended .

How should I optimize chromatin immunoprecipitation (ChIP) protocols when using SETDB1 antibodies?

For successful ChIP experiments with SETDB1 antibodies:

• Crosslinking optimization: Use 1% formaldehyde for 10-15 minutes at room temperature to preserve SETDB1-chromatin interactions

• Sonication conditions: Adjust sonication parameters to achieve chromatin fragments of 200-500 bp

• Antibody validation: Confirm SETDB1 binding at known target loci using ChIP-qPCR before proceeding to genome-wide analysis

• Controls: Include both positive and negative controls:

  • Positive controls: Known SETDB1 binding sites (e.g., endogenous retroviruses)

  • Negative controls: IgG antibody control and regions without SETDB1 binding

For ChIP-qPCR analysis, researchers successfully confirmed H3K9me3 signal and SETDB1 binding using the following approach: "We further confirmed H3K9me3 signal and SETDB1 binding at those solo and ensemble loci by ChIP-qPCR analysis... Setdb1 deletion diminished SETDB1 binding at those loci, indicating that the lack of H3K9me3 at the SETDB1 solo peaks is not due to artifacts of SETDB1 antibody."

What are the recommended antibody dilutions for different experimental applications?

The optimal dilution varies by antibody and application:

It is recommended to titrate each antibody in your specific testing system to obtain optimal results . The dilution may be sample-dependent, so checking validation data galleries provided by manufacturers can provide additional guidance.

How can I validate SETDB1 antibody specificity in my experimental system?

To validate SETDB1 antibody specificity:

• SETDB1 knockout/knockdown controls: Use SETDB1 knockout or knockdown samples as negative controls. For example, researchers confirmed antibody specificity by showing that "Setdb1 deletion diminished SETDB1 binding at those loci, indicating that the lack of H3K9me3 at the SETDB1 solo peaks is not due to artifacts of SETDB1 antibody."

• Multiple antibody validation: Use antibodies from different sources or those targeting different epitopes to confirm results.

• Western blot analysis: Confirm a single band of expected size (170-180 kDa).

• Immunofluorescence with known localization patterns: SETDB1 should primarily show nuclear localization consistent with its role in chromatin modification .

• Peptide competition assay: Pre-incubation with the immunizing peptide should abolish specific staining.

• Positive control tissues: Use tissues known to express SETDB1, such as HeLa cells, HEK-293 cells, or testicular tissue .

How does SETDB1 regulate B cell development and what methods can be used to study this process?

SETDB1 plays a critical role in B cell development through several mechanisms:

• Pro-B to pre-B cell transition: SETDB1 mediates this crucial transition in B cell development. Studies by Collins and colleagues demonstrated that "deletion of SETDB1 using an Mb1-CRE transgene targeting floxed SETDB1 in pre-B cells specifically leads to eradication of B cell population in bone marrow and spleen."

• Endogenous retrovirus (ERV) repression: SETDB1 represses ERVs to promote B cell lineage differentiation and maturation. "Upregulation of ERVs happens due to decreased histone H3K9 methylation at specific ERV loci. SETDB1 deletion correlates with induced expression of genes related to innate immunity, non-hematopoietic lineages, and even T cell specific genes."

• Retrotransposon silencing: SETDB1 silences retrotransposons (particularly MLV) to protect cell vitality. Without SETDB1, MLV upregulation "alters chromatin structure and triggers the unfolded protein response (UPR), inducing apoptosis."

Methods to study SETDB1 in B cell development:

• Conditional knockout models (e.g., using Mb1-CRE)

• RNA-seq to identify SETDB1-regulated gene expression patterns

• ChIP-seq to map SETDB1 binding sites and H3K9me3 marks

• Flow cytometry to analyze B cell populations at different developmental stages

• Western blotting with SETDB1 antibodies to confirm protein expression

What role does SETDB1 play in T cell function and how can researchers investigate this?

SETDB1 regulates T cell function through several mechanisms:

• Cytokine promoter methylation: "SETDB1 alters T cell function by methylating IL-2 and IL-17 promoters and mediating T cell lineage commitment and development."

• T cell lineage commitment: SETDB1 influences T cell developmental pathways.

• ERV silencing: SETDB1 silences endogenous retroviruses in T cells, which can indirectly affect immune responses.

• CD1a repression: "SETDB1 represses transcription of CD1a, a membrane protein that regulates the presentation of antigens on T cells... SETDB1 is first conscripted to the CD1a promoter by the td-piR(Glu)/PIWIL4 complex. After methylation of H3K9, SETDB1 recruits HP1β to sustain the chromatin modification."

Research methods to investigate SETDB1 in T cells:

• ChIP-seq to identify SETDB1 binding sites at cytokine promoters

• Luciferase reporter assays to measure promoter activity

• RT-qPCR to quantify cytokine expression levels

• Flow cytometry to analyze T cell subpopulations

• Immunofluorescence to visualize SETDB1 localization in different T cell subsets

• CRISPR-Cas9 knockout/knockdown followed by functional T cell assays

How is SETDB1 involved in the antiviral response and what techniques can visualize this activity?

SETDB1 plays several roles in antiviral responses:

• Viral latency regulation: SETDB1 contributes to the establishment and maintenance of HCMV latency by working with KAP1 and HP1α. "SETDB1 is recruited by the KAP1 bromodomain through SUMOylation to induce HCMV latency. HCMV leaves latency if KAP1 is specifically phosphorylated and loses the power to recruit SETDB1 for transcriptional silencing."

• Silencing unintegrated retroviral DNA: SETDB1 works with the HUSH complex and NP220 to silence unintegrated retroviral DNA. "Knockout of SETDB1 halted the silencing of unintegrated retroviral DNA in HeLa cells."

• Repression of retrotransposable elements: SETDB1 represses LINEs and satellite repeats in AML cells. "In the absence of SETDB1, a cytosolic nucleic acid-sensing cascade and IFN-mediated cell death is induced."

Techniques to visualize SETDB1 antiviral activity:

• ChIP-seq to map SETDB1 binding to viral DNA

• Co-immunoprecipitation to demonstrate interactions with viral proteins or antiviral factors

• Immunofluorescence to visualize colocalization with viral components

• Proximity ligation assay (PLA) to detect protein-protein interactions in situ

• Reporter virus assays (e.g., GFP-tagged viruses) combined with SETDB1 manipulation

• RNA-seq to identify ERVs and other retrotransposable elements regulated by SETDB1

How can SETDB1 antibodies be used to study tumor immunogenicity?

SETDB1 antibodies can be valuable tools for investigating tumor immunogenicity through several approaches:

• Immunohistochemistry (IHC) of tumor specimens:

  • Use SETDB1 antibodies at 1:500-1:2000 dilution to assess SETDB1 expression in patient tumor samples

  • Correlate SETDB1 expression with immune cell infiltration and clinical outcomes

• ChIP-seq analysis of SETDB1 targets in tumor cells:

  • Map SETDB1 binding sites in cancer cells to identify genes involved in immune regulation

  • Identify differences in binding patterns between cancer types and correlate with immunogenicity

• Co-immunoprecipitation (Co-IP) studies:

  • Use SETDB1 antibodies to pull down SETDB1 and associated proteins

  • Identify interactions with factors involved in immune regulation (e.g., TRIM28/KAP1 complex)

• Proximity Ligation Assay (PLA):

  • Visualize protein-protein interactions between SETDB1 and immune regulatory factors in situ

Research has shown that "SETDB1 overexpression represses production and infiltration of antitumour immune cells, mediates immune escape through TE and ERV silencing, represses the type I interferon pathway, and interferes in immune checkpoint blockade (ICB) outcomes by regulation of PD-L1 expression and IFN signalling." Using SETDB1 antibodies, researchers can further investigate these mechanisms in different cancer types.

How does SETDB1 expression correlate with different immune cell infiltration in tumors?

SETDB1 expression shows complex correlations with immune cell infiltration in tumors:

• CD8+ T cell infiltration: SETDB1 typically shows a negative correlation with CD8+ T cell infiltration in tumors. "Patient TCGA data further illustrated SETDB1 negative correlation with CD8+ T cell infiltration in tumors as well as Granzyme B expressing activated T cells."

• Cancer-associated fibroblasts (CAFs): "Infiltration of cancer-associated fibroblasts (CAFs), which often play a role in tumor stroma and cancer progression have marked positive correlation with SETDB1."

• Various immune cell types: SETDB1 shows positive correlation with "other types of immune cells such as CD8+ T cells, CD4+ T cells, Tregs, and B cells."

• Cancer-specific associations: The association of SETDB1 with different immune subtypes varies by cancer type: "Strong association of SETDB1 with different immune subtypes was observed in many different cancers including lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), and glioblastoma (GBM)."

• HLA-related genes: "SETDB1 demonstrated a negative correlation with HLA-related genes in all cancers, with the exception of adenoid cystic carcinoma (ACC), clear cell renal cell carcinoma (KIRC), and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC)."

These correlations can be studied using SETDB1 antibodies in multiplex immunofluorescence staining, tissue microarray analysis, and digital pathology approaches to quantify immune cell infiltration and SETDB1 expression simultaneously.

What methodologies can evaluate SETDB1-mediated immune escape in cancer cells?

Several methodologies can be employed to evaluate SETDB1-mediated immune escape in cancer cells:

• CRISPR-Cas9 gene editing:

  • Knockout or knockdown SETDB1 in cancer cell lines

  • Assess changes in immune escape mechanisms

  • Example: "Lin and colleagues conducted a CRISPR-Cas9 gRNA screening in ID8 cells... their result proved SETDB1 as a critical histone modifier negatively regulating PD-L1 level working alongside TRIM28/KAP1 complex in ovarian cancer."

• ChIP-seq and RNA-seq analysis:

  • Identify SETDB1 binding sites and correlate with gene expression changes

  • Focus on genes involved in immune recognition and evasion

  • Example: "Comparing samples with high levels of SETDB1 to samples with low levels of SETDB1 in ADC and SCC revealed distinct gene signatures... pathways related to immune responses and EMT processes were largely diminished in high level SETDB1 populations among both subtypes."

• Co-culture systems with immune cells:

  • Culture SETDB1-manipulated cancer cells with immune cells

  • Evaluate changes in immune cell activation, cytokine production, and cancer cell killing

• PD-L1 expression analysis:

  • Assess correlation between SETDB1 and PD-L1 expression

  • Example: "SETDB1 downregulation in turn led to activation of ERVs which triggered the dsRNA sensing pathway and consecutively the activation of interferon signaling."

• Flow cytometry for immune checkpoint molecules:

  • Analyze expression of immune checkpoint molecules in SETDB1-manipulated cancer cells

  • Assess immune recognition markers

• Mouse tumor models:

  • Generate SETDB1-knockout or overexpressing tumor models

  • Assess tumor growth, immune infiltration, and response to immunotherapy

Why might I observe different molecular weights for SETDB1 in Western blots?

Researchers may observe different molecular weights for SETDB1 in Western blots for several reasons:

• Post-translational modifications: SETDB1 undergoes various post-translational modifications that can alter its apparent molecular weight. As noted, "The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors."

• Antibody specificity: Different antibodies may recognize different epitopes or isoforms of SETDB1:

  • Mouse monoclonal antibody (clone 5H6D4) detects a band of approximately 180 kDa in HEK293 cell lysates

  • Other antibodies detect bands in the 170-180 kDa range

• Species differences: SETDB1 proteins from different species may have slightly different molecular weights and modification patterns.

• Sample preparation: Differences in sample preparation (e.g., different lysis buffers, presence of protease inhibitors) can affect the integrity and apparent size of SETDB1.

• Gel percentage and running conditions: SDS-PAGE gel percentage and running conditions can influence the migration and apparent molecular weight of proteins.

To address these variations, researchers should:

• Include positive controls with known SETDB1 expression

• Use multiple antibodies targeting different epitopes

• Include molecular weight markers

• Document precise experimental conditions

What controls should I include when using SETDB1 antibodies in ChIP experiments?

For robust ChIP experiments with SETDB1 antibodies, include these essential controls:

• Input control:

  • Save a portion of the chromatin before immunoprecipitation

  • Use to normalize ChIP data and account for differences in starting material

• Negative antibody control:

  • Perform ChIP with non-specific IgG of the same species and isotype as the SETDB1 antibody

  • Establishes background signal level

• SETDB1 knockout/knockdown control:

  • Include samples where SETDB1 is deleted or reduced

  • Confirms antibody specificity

  • Example: "Setdb1 deletion diminished SETDB1 binding at those loci, indicating that the lack of H3K9me3 at the SETDB1 solo peaks is not due to artifacts of SETDB1 antibody."

• Positive genomic controls:

  • Include primer sets for regions known to be bound by SETDB1 (e.g., endogenous retroviruses)

  • Confirms successful immunoprecipitation

• Negative genomic controls:

  • Include primer sets for regions not bound by SETDB1

  • Confirms specificity of enrichment

• Histone mark controls:

  • Consider parallel ChIP for H3K9me3, which is deposited by SETDB1

  • Example: "We further confirmed H3K9me3 signal and SETDB1 binding at those solo and ensemble loci by ChIP-qPCR analysis."

• Technical replicates:

  • Perform at least three technical replicates to ensure reproducibility

  • Include biological replicates when possible

How should I interpret conflicting SETDB1 expression data between different techniques?

When faced with conflicting SETDB1 expression data between different techniques, consider these factors:

• Technique-specific limitations:

  • Western blotting measures total protein levels but may miss localized changes

  • Immunohistochemistry reveals spatial distribution but is less quantitative

  • qPCR measures mRNA but not protein levels

  • ChIP detects chromatin binding but not total protein

• Antibody differences:

  • Different antibodies may recognize different epitopes or isoforms

  • Some antibodies work better in specific applications

  • Example conflict from research: "This result disagrees with the previously mentioned paper that identified SETDB1 as an inducer of PD-L1, promoting immune escape in CRC."

• Context-dependent regulation:

  • SETDB1 function may vary by cell type or condition

  • Example: "Mechanistically, in ovarian cancer, the SETDB1 knockout developed mitotic defects in the G2-M phase resulting in formation of micronuclei. The micronuclei then stimulated ISG upregulation through cGAS-STING pathway, which resulted in increased PD-L1 expression."

• Resolution strategies:

  • Use multiple antibodies in each technique

  • Include additional complementary techniques

  • Consider genetic manipulation (knockout/knockdown) to validate findings

  • Investigate cell type-specific differences

  • Example approach: "SETDB1 downregulation in turn led to activation of ERVs which triggered the dsRNA sensing pathway and consecutively the activation of interferon signaling. This work showed that SETDB1 repression can activate IFN signaling not only through cGAS-STING cytosolic DNA sensing pathway but also through RNA sensing mechanism."

Remember that conflicting data often provides opportunities for new discoveries about context-dependent functions or regulatory mechanisms.